<DOC>
	<DOCNO>NCT01033032</DOCNO>
	<brief_summary>Doxorubicin integral part treatment woman breast cancer many year . Since amrubicin may activity doxorubicin , well less cardiotoxicity , evaluation amrubicin treatment advance breast cancer priority . In Phase II study , investigator propose evaluation single-agent amrubicin second- third-line treatment woman metastatic breast cancer .</brief_summary>
	<brief_title>Trial Amrubicin Treatment Patients With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>This phase I/II study phase I evaluate maximum tolerate dose amrubicin , phase II ass progression free survival patient HER2-negative metastatic breast cancer use dose establish phase I portion .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<criteria>1 . Females &gt; =18 year age . 2 . Histologic diagnosis HER2negative breast cancer . HER2 negativity must confirm one following : FISHnegative ( FISH ratio &lt; 2.2 ) , IHC 01+ , IHC 23+ AND FISHnegative ( FISH ratio &lt; 2.2 ) 3 . Evidence metastatic locally advanced , inoperable breast cancer . 4 . Minimum 1 maximum 2 prior metastatic breast cancer chemotherapy regimens . 5 . Patients prior anthracycline therapy eligible , provide previous anthracycline ≥6 month prior study entry . 6 . Measurable disease per RECIST criterion version 1.1 7 . Left ventricular ejection fraction ( LVEF ) ³50 % echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) . 8 . Patients must QTc interval &lt; =450 msec . 9 . No intercurrent significant medical condition cardiac illness . 10 . Patients must &gt; =3 week since last chemotherapy , recover acute toxicity , exception alopecia . 11 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 . 12 . Adequate organ function include follow : ANC &gt; =1500 cells/mL Platelet count &gt; =100,000 cells/mL Hemoglobin &gt; =9 g/dL Total bilirubin &lt; =1.5 x ULN ; AST/ALT &lt; =2.5 x ULN , ( except due hepatic metastasis , &lt; =5 x ULN ) Serum creatinine &lt; 1.5 x ULN 13 . Women childbearing potential must negative serum urine pregnancy test perform &lt; =7 day prior start treatment . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . 14 . Patients must accessible treatment followup . 15 . Patients must able understand investigational nature study give write informed consent prior study entry . 16 . Patients anticoagulation acceptable therapeutic anticoagulation stable . Additionally , patient 's INR must adequate patient receive treatment coumadin . 17 . Prior hormonal therapy metastatic breast cancer permit ; however , therapy must discontinue prior patient 's enrollment study . 1 . Any concurrent therapy investigational , chemotherapeutic , hormonal therapy . 2 . Prior treatment &gt; =3 regimens cytotoxic therapy advance disease setting . ( Any number previous hormonal therapy acceptable , long therapy discontinue prior patient 's enrollment study ) . 3 . Major surgery systemic therapy &lt; =3 week study treatment . 4 . Prior highdose chemotherapy require hematopoietic stem cell support . 5 . Prior radiation therapy &gt; 25 % bone marrow . 6 . Uncontrolled brain metastasis . Patients treat brain metastasis ( resection radiotherapy ) eligible brain metastasis respond treatment document CT MRI scan obtain &gt; =2 week completion radiation therapy , neurologic symptom absent , steroid discontinue . 7 . Suspected , diffuse idiopathic interstitial lung disease pulmonary fibrosis . 8 . Diagnosis second malignancy within last 3 year ( exception carcinoma situ cervix , squamous basal cell skin cancer , thyroid cancer , ductal carcinoma situ [ DCIS ] , lobular carcinoma situ [ LCIS ] ) . 9 . Any following &lt; =12 month prior start study treatment : myocardial infarction ; severe unstable angina ; congestive heart failure ; ongoing cardiac dysrhythmia . 10 . Family history idiopathic cardiomyopathy uncontrolled heart arrhythmia . 11 . Patients previous allergy hypersensitivity anthracyclines . 12 . Patients ≥10 % drop LVEF previous anthracycline therapy . 13 . Palliative radiotherapy area metastatic breast cancer must complete &gt; 7 day prior first dose study treatment . The exception radiotherapy brain metastasis , must complete &gt; =21 day prior study treatment . ( Note : Any measurable lesion previously irradiate consider target lesion ) . 14 . Concurrent severe , intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 15 . History seropositive HIV , patient receive immunosuppressive medication increase risk neutropenic complication . 16 . Mental condition would prevent patient comprehension nature , risk associate , study . 17 . Use nonapproved investigational agent &lt; =30 day administration first dose study drug . Patients may receive investigational anticancer treatment participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Amrubicin</keyword>
</DOC>